What the business is, and whether it's a good one at a fair price.
Markets established pharmaceutical brands in India across pain (Voveran), calcium supplementation (Calcium Sandoz, Macalvit, Citromacalvit), neurosciences (Tegrital), gynaecology and transplant immunology. For FY26, revenue from operations stood at Rs 354.33 crore with net profit of Rs 93.18 crore and total assets of Rs 978.27 crore. In Q1 FY27, revenue from operations rose to INR 1,038.1 million from INR 875.5 million, with PAT of INR 322.1 million and the company reporting zero outstanding debt. On July 29, 2026, ChrysCapital-backed entities (WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners) completed the acquisition of Novartis AG's 70.68% stake (1,74,50,680 equity shares) for about Rs 1,376.89 crore. Under new management, the board approved a 5-year distribution deal with Novartis Pharma Services AG, a brand license for Tegrital, and the assignment of the Voveran, Macalvit and Citromacalvit trademarks, with a new corporate identity and website (nilpharma.co.in) to follow. Stated cost categories in FY26 were employee costs at 5.9% of revenue and other operating expenses at 11.5%, with depreciation at 0.6% and capex at 0.1%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from NOVARTIS INDIA LIMITED's filed financials and exchange disclosures
NOVARTIS INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol NOVARTIND.
Yes. Over the trailing twelve months NOVARTIS INDIA LIMITED reported a net profit of ₹93 Cr on revenue of ₹354 Cr.
Yes. The dividend yield is 1.06% at the current price. It paid out 66% of its profit as dividend in FY26.
Effectively yes. It holds ₹53 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, NOVARTIS INDIA LIMITED ranks 142 of 169 in Pharmaceuticals — cheaper than 16% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session NOVARTIS INDIA LIMITED moves 1.66% — that is the median absolute close-to-close move across its last 100 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by NOVARTIS INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
